Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06620523

Prevent Cardiac Surgery Associated AKI Trial

Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)

Sponsor: George Washington University

Conditions Coronary Artery Disease Renal Failure Surgery Surgery-Complications

Interventions CoQ10 1200 mg orally with Glutathione 1000 mg orally Group B: Placebo CoQ10 orally and Placebo Glutathione orally

Updated 3 times since 2024 Last updated: Oct 3, 2025 Started: Jul 18, 2024 Primary completion: Jun 17, 2027 Completion: Jun 17, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Coronary Artery Disease and Renal Failure and is currently actively recruiting participants. George Washington University leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

3 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Oct 2024 — Sep 2025 [monthly]

Recruiting PHASE2

First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

George Washington University

Data source: George Washington University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Washington D.C., United States